Healthcare
EyePoint Pharmaceuticals, Inc.(EYPT)
Live Price
Offline$13.03
+4.24% today
1Y Change
+14.61%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $1.12B
- Revenue Growth
- -27.5%
- EPS Growth
- -36.6%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
EyePoint Pharmaceuticals, Inc. (EYPT) is a Healthcare stock with a market cap of $1.12B and listed on NASDAQ. The stock last traded around $13.03 and up 14.6% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -27.5%, EPS growth of -36.6%, a dividend yield of 0.0%. What stands out right now is revenue -27.5%, EPS -36.6%, free cash flow -86.8% with operating margin -776.0% and ROIC -97.0%. Valuation already assumes a fairly strong business story at price/sales 35.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines EYPT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-27.5% vs +7.6% peer median
Operating Margin
Below sector median
-776.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -27.5% and EPS is at -36.6%, with operating margin around -776.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | +0.4% | +0.6% | -8.2% |
2026 Mar 4, 2026 | -3.9% | -12.4% | -17.1% | -27.7% |
2025 Nov 5, 2025 | -10.4% | +0.5% | +8.8% | +51.7% |
Benchmark Edge
EYPT vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EYPT
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EYPT Max Drawdown
-39.26%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EYPT and SPY.
Company Overview
EyePoint Pharmaceuticals, Inc.
NASDAQ Global Market
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
- Leadership
- Jay S. Duker
- IPO Date
- Jan 27, 2005
- Employees
- 165
- Street Address
- 480 Pleasant Street
- Mailing
- Watertown, MA, 02472
- Region
- Watertown, MA, US
- Reporting Currency
- USD
- Investor Line
- 617 926 5000
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 35.7
- Price/Book
- 4.8
Growth
- Revenue
- -27.5%
- EPS
- -36.6%
- Free Cash Flow
- -86.8%
Profitability
- Gross Margin
- 93.4%
- Operating Margin
- -776.0%
- Net Margin
- -739.4%
- ROE
- -94.4%
- ROIC
- -97.0%
Balance Sheet
- Debt/Equity
- 0.09
- Current Ratio
- 6.66
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.